Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus vaccine in a case with ties to U.S. Department of Health and Human Services Secretary Robert F.

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around Robert F.

Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the trial.